Nh-Amundi Hanaro MSCI Virology ETF (KRX:432850)
South Korea
· Delayed Price · Currency is KRW 10,260
+170 (1.68%)
Last updated: Jun 4, 2025
-12.57% (1Y)
| Assets | 1.52B |
| Expense Ratio | 0.50% |
| PE Ratio | 15.05 |
| Dividend (ttm) | 45.00 |
| Dividend Yield | 0.42% |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | -12.57% |
| Volume | 1,200 |
| Open | 10,200 |
| Previous Close | 10,090 |
| Day's Range | 10,195 - 10,260 |
| 52-Week Low | 9,660 |
| 52-Week High | 12,410 |
| Beta | n/a |
| Holdings | 10 |
| Inception Date | Jun 8, 2022 |
About 432850
432850.KQ was created on 2022-06-08 by Amundi. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 1514.09m in AUM and 23 holdings.
Asset Class Equity
Category Health Care
Stock Exchange Korea Stock Exchange
Ticker Symbol 432850
Provider Amundi
Index Tracked MSCI World IMI Virology Select Index - KRW - Benchmark TR Net
Performance
432850 had a total return of -12.57% in the past year, including dividends. Since the fund's inception, the average annual return has been 0.90%.
Top 10 Holdings
86.93% of assets| Name | Symbol | Weight |
|---|---|---|
| Gilead Sciences, Inc. | GILD | 11.72% |
| GSK plc | GSK | 10.82% |
| Johnson & Johnson | JNJ | 10.38% |
| Sanofi | SAN | 10.04% |
| Pfizer Inc. | PFE | 9.17% |
| Merck & Co., Inc. | MRK | 8.80% |
| Eli Lilly and Company | LLY | 7.40% |
| AbbVie Inc. | ABBV | 7.02% |
| Moderna, Inc. | MRNA | 6.24% |
| Vaxcyte, Inc. | PCVX | 5.33% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Apr 29, 2024 | 45.000 KRW | May 3, 2024 |
| Jan 30, 2024 | 50.000 KRW | Feb 2, 2024 |
| Jul 28, 2023 | 50.000 KRW | Aug 2, 2023 |
| Apr 27, 2023 | 45.000 KRW | May 3, 2023 |
| Oct 28, 2022 | 35.000 KRW | Nov 2, 2022 |